What's Trending in Stocks Right Now
Discover which stock market news stories are capturing the most attention today. This page shows you the most-viewed articles on StockTitan, updated every minute based on real visitor traffic. See what tens of thousands of traders and investors are reading right now.
Why this matters: When a news story suddenly gets massive readership, it often indicates significant market interest in that stock or sector. By tracking the most popular articles, you can quickly identify which companies and events are drawing investor attention and potentially moving markets.
This isn't editorial content or sponsored placement—it's based purely on reader activity. Every story below earned its position through actual page views from real visitors, making this an authentic snapshot of what the trading community finds most interesting. Whether it's earnings reports, FDA decisions, merger news, or market analysis, the most-read stories rise to the top.
Updated Every Minute: Market sentiment shifts quickly. This ranking is recalculated every 60 seconds to reflect the latest reading trends. What's trending now could be completely different in an hour as new stories break and capture attention.
TeraWulf (NASDAQ:WULF) has secured two major 10-year HPC colocation agreements with Fluidstack to deliver over 200 MW of critical IT load at its Lake Mariner data center campus. The agreements represent approximately $3.7 billion in contracted revenue over the initial term, with potential to reach $8.7 billion if extension options are exercised.
Google will backstop $1.8 billion of Fluidstack's lease obligations and receive warrants for approximately 41 million shares (8% equity stake) in TeraWulf. The deployment schedule targets 40 MW online by H1 2026, with full 200+ MW capacity expected by year-end 2026. The Lake Mariner facility features dual 345 kV transmission lines, closed-loop water cooling, and ultra-low-latency fiber connectivity.
- None.
- Significant capital expenditure required ($8-$10 million per MW)
- 8% equity dilution through Google warrants
- Additional capital markets funding needed for project completion
Trinity Biotech (Nasdaq: TRIB) has received New York State Department of Health (NYSDOH) approval to launch its FDA-cleared PreClara™ Ratio biomarker test for preeclampsia risk assessment in Q3 2025. The test measures sFlt-1/PlGF ratio to evaluate progression risk to severe preeclampsia in hospitalized patients with hypertensive pregnancy disorders.
The test addresses a significant medical need, as approximately 500,000 U.S. women are affected annually by hypertensive pregnancy disorders. Recent studies show potential cost savings exceeding $10 million per 1,000 patients through reduced preterm deliveries and NICU admissions. This approval also supports the future launch of PrePsia™, Trinity's early pregnancy risk assessment technology.
- FDA-cleared PreClara test addresses large market of 500,000 affected U.S. women annually
- Demonstrated cost savings potential of over $10M per 1,000 patients
- Strategic expansion into maternal health diagnostics market
- Regulatory approval enables Q3 2025 commercial launch
- Groundwork laid for future PrePsia technology launch
- None.
Gorilla Technology (NASDAQ:GRRR) reported strong H1 2025 financial results, with revenue reaching $39.3 million, representing a 90.2% year-over-year growth. The company successfully completed a $105 million equity offering in July 2025 and reduced its debt to $18.1 million from $21.4 million at 2024 year-end.
The company secured three new strategic contracts with Port of Tyne (UK), Wan Hai Port, and ADE Corporation (Taiwan). Despite reporting an operating loss of $9.1 million, Gorilla's Adjusted EBITDA was positive at $5.7 million. The company's project pipeline now exceeds $5 billion, supported by expansion across multiple global regions.
- Revenue grew 90.2% year-over-year to $39.3 million in H1 2025
- Successfully raised $105 million through equity offering in July 2025
- Reduced debt by $3.3 million from year-end 2024
- Secured three new strategic contracts in UK and Taiwan
- Project pipeline exceeded $5 billion
- Adjusted EBITDA positive at $5.7 million
- Strong cash position with $26.1 million in total cash at end of H1
- Operating loss (IFRS) of $9.1 million in H1 2025
- Net loss of $8.5 million for the period
- Significant currency exchange losses of $12.6 million due to Egyptian pound devaluation
- Loss per share of $0.43
Aeries Technology (NASDAQ: AERT) reported exceptional Q1 FY2026 results, marking its strongest first quarter ever. The company achieved $15.3 million in revenue and turned profitable with $1.7 million in net income, representing a remarkable $17.0 million improvement from the previous year's loss.
Key financial highlights include $0.8 million in operating profit, $2.3 million in EBITDA, and positive operating cash flow of $1.4 million. The company successfully reduced SG&A expenses by over 85% year-over-year. Aeries reaffirmed its FY2026 guidance, projecting revenue of $74-80 million and adjusted EBITDA of $6-8 million.
The turnaround stems from strategic initiatives including streamlined operations, enhanced cost controls, and focus on AI-powered Global Capability Center (GCC) services, particularly targeting Private Equity-backed companies.
- Achieved first cash flow positive quarter with $1.4 million from operations
- Dramatic $17.0 million net income improvement year-over-year
- SG&A expenses reduced by over 85% year-over-year
- Operating profit of $0.8 million, up $17.2 million from previous year
- Strong revenue guidance of $74-80 million for FY2026
- Secured multiple new Private Equity client wins
- Revenue of $15.3 million shows limited absolute growth
- Adjusted EBITDA of $1.0 million indicates thin margins
- Exit from non-core operations may impact revenue diversification
OneMedNet (NASDAQ:ONMD), an AI-powered Real-World Data company, reported significant financial improvements in Q2 2025. The company achieved an 80% reduction in total liabilities, decreasing from $19.7M to $6.2M, with an additional $1.9M reduction in July 2025.
Key financial highlights include $3.0M net income in Q2 2025, $3.7M raised through private placements, and holdings of 15 BTC valued at $1.6M. Operationally, OneMedNet expanded its provider network to 1,750 sites with access to 136M clinical studies, while enhancing its iRWD™ platform with improved AI capabilities and adding over 5 billion administrative records and claims.
- Significant debt reduction of 80%, improving balance sheet strength
- Net income of $3.0M in Q2 2025 and $1.1M YTD
- Successful private placement raising $3.7M, including $1.2M from insiders
- Strategic bitcoin holdings of 15 BTC valued at $1.6M
- Network expansion to 1,750 provider sites with access to 136M clinical studies
- Platform enhancement with 5B+ administrative records and claims data
- Significant portion of net income ($5.0M) came from debt settlements rather than operations
- Reliance on private placements for operational funding
Biomerica (Nasdaq: BMRA) has received approval from the UAE Ministry of Health and Prevention for its Fortel® Ulcer Test for home use. This 10-minute diagnostic test detects antibodies to Helicobacter pylori (H. pylori), a bacterium affecting 41% of the UAE population and linked to approximately 80% of gastric cancer cases.
The test will be distributed through UAE-based partners and made available at pharmacies, clinics, and online platforms. H. pylori, classified as a Class 1 carcinogen by WHO, can lead to serious complications in up to 20% of infected individuals if untreated, including peptic ulcers and gastric cancer. This approval strengthens Biomerica's presence in the Middle East market, following their successful launch of the EZ Detect™ Colon Disease Test.
- Regulatory approval in UAE expands market access for Fortel® Ulcer Test
- Large target market with 41% of UAE population affected by H. pylori
- Strategic partnerships with UAE distributors for widespread distribution
- Strengthens company's Middle East presence following previous successful product launches
- Faces competition in a market with existing H. pylori testing solutions
- Success dependent on consumer adoption of home testing concept
HydroGraph (OTCQB: HGRAF) has announced a strategic partnership with Hawkeye Bio and Ease Healthcare to develop LEAP™, an innovative lung cancer screening test. The test, powered by HydroGraph's ultra-pure graphene, is a non-invasive blood test showing a 99.8% negative predictive value for early lung cancer detection.
The LEAP test targets high-risk populations including smokers, military personnel, and first responders. With current screening compliance at only 2-6% of at-risk individuals, LEAP aims to improve early detection rates among the 15-19.3 million US individuals eligible for annual screening. The technology leverages Hawkeye Bio's patented graphene biosensors, which measure enzymatic activity associated with inflammatory disease.
- Test demonstrates exceptional 99.8% negative predictive value for lung cancer detection
- Technology addresses a large market with 15-19.3 million eligible screening candidates in the US
- Future expansion potential to detect 14 different cancers, Alzheimer's, and Multiple Sclerosis
- Global patent protection across major markets including US, UK, EU, Japan, Korea, Hong Kong, and Taiwan
- Current lung cancer screening compliance remains very low at 2-6% of at-risk individuals
- Product still needs to establish market adoption and penetration
Ulta Beauty (NASDAQ: ULTA) and Target Corporation (NYSE: TGT) have announced they will end their shop-in-shop partnership in August 2026 when their current agreement expires. The partnership, which began in 2021, allowed Target customers to access prestige beauty products and link their Ulta Beauty Rewards with Target Circle accounts.
Until the conclusion of the partnership, customers will continue to earn Ulta Beauty Rewards on eligible purchases at Target locations. Ulta Beauty plans to focus on its core business strategy, including the launch of Ulta Beauty Marketplace later this year. Target will maintain its beauty retail presence by continuing to offer a curated assortment of beauty products and experiences to its customers.
- Customers can continue earning Ulta Beauty Rewards at Target until August 2026
- Ulta Beauty plans to launch new Marketplace platform later this year
- Both companies maintain strong independent beauty retail strategies
- Loss of strategic retail partnership that expanded Ulta's market reach
- Potential reduction in customer convenience and cross-shopping opportunities
- Discontinuation of prestige beauty offerings through Target's platform
Tilray Brands (Nasdaq: TLRY) has submitted an application for an extension to regain compliance with Nasdaq's minimum share price listing requirements. The company is considering several options, including a potential stockholder-approved Reverse Stock Split to maintain its Nasdaq listing.
CEO Irwin Simon noted that Tilray's stock has seen recent appreciation following President Trump's cannabis rescheduling review, which he believes reflects investor confidence in the company's global platform. The company aims to leverage its position in cannabis, beverage, and wellness industries while giving the market additional time to recognize its business strategy value.
- None.
- Risk of potential delisting from Nasdaq due to share price non-compliance
- Possible reverse stock split which could be viewed negatively by market
- Regulatory uncertainty affecting business operations